Enterprise Therapeutics Ltd, formed in May 2014, is an early stage drug discovery company focussed on research and development of novel therapies for the treatment of respiratory diseases.In October, 2020 -Forbion announced that its portfolio company, Enterprise Therapeutics Ltd (Enterprise)’s novel TMEM16A potentiator portfolio has been fully acquired by Roche for Treatment of Cystic Fibrosis and Other Respiratory Diseases.In October 2020, Roche acquired Enterprise Therapeutics' ETD-002. Enterprise would receive upfront payment of GBP 75 million, and predetermined milestones.In April 2018, the company closed an oversubscribed £29 million ($41 million USD) series B round.In November 2016, the company closed GBP 4 million (US $5 million) fund raising.In February 2015, the company raised GBP 1.6 million (US $2.4 million) in initial series A financing from Epidarex capital. In August 2015, the company had secured an additional GBP 2.4 million (US $3.7 million